T2DM/Peripheral Neuropathy subjects needed for clinical trial

Sponsored by Winsantor, The University of Alberta and other research institutes are conducting a randomized outpatient, double-blind, placebo-controlled, multiple-site study of the safety, tolerability, and exploratory efficacy of topically administered WST-057 (4% pirenzepine free base monohydrate) for 24 weeks in subjects with T2DM with peripheral neuropathy.   For information including the full list of eligibility criteria, click the web URL below.

If you fit the criteria and are interested in participating in this study, please contact:

Angela Hansen 858 848 483     email:  1ahansen@winsantorbio.com

or

Stan Kim 858 336 8094  email: skim@winsantor.com